Applied DNA Sciences Inc. Announces Initiation of Phase I Clinical Trial for CD123-specific CAR-T Cells Using Synthetic LineaDNA™ Technology

Reuters09-23

<a href="https://laohu8.com/S/APDN">Applied DNA Sciences Inc</a>. Announces Initiation of Phase I Clinical Trial for CD123-specific CAR-T Cells Using Synthetic LineaDNA™ Technology

Applied DNA Sciences, Inc. (NASDAQ:APDN), a biotechnology company specializing in nucleic acid production solutions for the biopharmaceutical and diagnostics sectors, has announced the initiation of a Phase I clinical trial. This trial focuses on CD123-specific CAR-T cells produced using the synthetic LineaDNA™-based piggyBac transposon system. The study is aimed at patients with acute myeloid leukemia (AML) and will be presented at the 10th Annual CAR-TCR Summit in Boston. The presentation is scheduled for September 23, 2025, at 6:30 p.m. Eastern time.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied DNA Sciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1077175) on September 23, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2569902287?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-23 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569902287","market":"fut","top_or_hot":-1,"title":"Applied DNA Sciences Inc. Announces Initiation of Phase I Clinical Trial for CD123-specific CAR-T Cells Using Synthetic LineaDNA™ Technology","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/APDN\">Applied DNA Sciences Inc</a>. Announces Initiation of Phase I Clinical Trial for CD123-specific CAR-T Cells Using Synthetic LineaDNA™ Technology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/APPDW\">Applied DNA Sciences, Inc.</a> (NASDAQ:APDN), a biotechnology company specializing in nucleic acid production solutions for the biopharmaceutical and diagnostics sectors, has announced the initiation of a Phase I clinical trial. This trial focuses on CD123-specific CAR-T cells produced using the synthetic LineaDNA™-based piggyBac transposon system. The study is aimed at patients with acute myeloid leukemia (AML) and will be presented at the 10th Annual CAR-TCR <a href=\"https://laohu8.com/S/SMMT\">Summit</a> in Boston. The presentation is scheduled for September 23, 2025, at 6:30 p.m. Eastern time.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/AMAT\">Applied</a> DNA Sciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1077175) on September 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Applied DNA Sciences Inc. Announces Initiation of Phase I Clinical Trial for CD123-specific CAR-T Cells Using Synthetic LineaDNA™ Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApplied DNA Sciences Inc. Announces Initiation of Phase I Clinical Trial for CD123-specific CAR-T Cells Using Synthetic LineaDNA™ Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-23 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/APDN\">Applied DNA Sciences Inc</a>. Announces Initiation of Phase I Clinical Trial for CD123-specific CAR-T Cells Using Synthetic LineaDNA™ Technology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/APPDW\">Applied DNA Sciences, Inc.</a> (NASDAQ:APDN), a biotechnology company specializing in nucleic acid production solutions for the biopharmaceutical and diagnostics sectors, has announced the initiation of a Phase I clinical trial. This trial focuses on CD123-specific CAR-T cells produced using the synthetic LineaDNA™-based piggyBac transposon system. The study is aimed at patients with acute myeloid leukemia (AML) and will be presented at the 10th Annual CAR-TCR <a href=\"https://laohu8.com/S/SMMT\">Summit</a> in Boston. The presentation is scheduled for September 23, 2025, at 6:30 p.m. Eastern time.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/AMAT\">Applied</a> DNA Sciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1077175) on September 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APDN","symbol_name":"Applied DNA Sciences","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL2nGmhB:1","article_id":"2569902287","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569902287","pubTimestamp":1758630614,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Applied DNA Sciences Inc. Announces Initiation of Phase I Clinical Trial for CD123-specific CAR-T Cells Using Synthetic LineaDNA Technology. Applied DNA Sciences, Inc. , a biotechnology company specializing in nucleic acid production solutions for the biopharmaceutical and diagnostics sectors, has announced the initiation of a Phase I clinical trial. This trial focuses on CD123-specific CAR-T cells produced using the synthetic LineaDNA-based piggyBac transposon system. The study is aimed at patients with acute myeloid leukemia  and will be presented at the 10th Annual CAR-TCR Summit in Boston. The presentation is scheduled for September 23, 2025, at 6:30 p.m. Eastern time.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied DNA Scie","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APDN":"Applied DNA Sciences","BK4583":"猴痘概念","BK4121":"生命科学工具和服务"},"translate_title":"Applied DNA Sciences Inc.宣布启动使用合成LineaDNA的CD123特异性CAR-T细胞的I期临床试验™技术","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APDN":0.9},"content_text":"Applied DNA Sciences Inc. Announces Initiation of Phase I Clinical Trial for CD123-specific CAR-T Cells Using Synthetic LineaDNA™ Technology\n    \n\nApplied DNA Sciences, Inc. (NASDAQ:APDN), a biotechnology company specializing in nucleic acid production solutions for the biopharmaceutical and diagnostics sectors, has announced the initiation of a Phase I clinical trial. This trial focuses on CD123-specific CAR-T cells produced using the synthetic LineaDNA™-based piggyBac transposon system. The study is aimed at patients with acute myeloid leukemia (AML) and will be presented at the 10th Annual CAR-TCR Summit in Boston. The presentation is scheduled for September 23, 2025, at 6:30 p.m. Eastern time.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied DNA Sciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1077175) on September 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2569902287","isCrawlerRequest":true}